Affiliation:
1. Mayo Clinic Arizona, Scottsdale, AZ; and
2. Princess Margaret Hospital, Toronto, ON
Abstract
Abstract
Cyclophosphamide, bortezomib, and dexamethasone (CyBorD) is highly effective in multiple myeloma. We treated patients with light chain amyloidosis (AL) before stem cell transplantation (ASCT), instead of ASCT in ineligible patients or as salvage. Treatment was a combination of bortezomib (1.5 mg/m2 weekly), cyclophosphamide (300 mg/m2 orally weekly), and dexamethasone (40 mg weekly). Seventeen patients received 2 to 6 cycles of CyBorD. Ten (58%) had symptomatic cardiac involvement, and 14 (82%) had 2 or more organs involved. Response occurred in 16 (94%), with 71% achieving complete hematologic response and 24% a partial response. Time to response was 2 months. Three patients originally not eligible for ASCT became eligible. CyBorD produces rapid and complete hematologic responses in the majority of patients with AL regardless of previous treatment or ASCT candidacy. It is well tolerated with few side effects. CyBorD warrants continued investigation as treatment for AL.
Publisher
American Society of Hematology
Subject
Cell Biology,Hematology,Immunology,Biochemistry
Reference22 articles.
1. Immunoglobulin light chain amyloidosis: 2011 update on diagnosis, risk stratification, and management.;Gertz;Am J Hematol,2011
2. AL amyloidosis: the last 30 years.;Skinner;Amyloid,2000
3. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis.;Dispenzieri;J Clin Oncol,2004
4. Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score.;Kumar;Mayo Clin Proc,2011
5. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone and colchicine.;Kyle;N Engl J Med,1997
Cited by
319 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献